Probiodrug Announces Supervisory Board Changes

Appointment of Claus Braestrup as Chairman of the Supervisory Board

16-Jun-2010 - Germany

Probiodrug AG (Probiodrug) announced that Dr Claus Braestrup, former President and CEO of H. Lundbeck A/S, has been appointed as a new member of the Supervisory Board and has been elected as its new Chairman. Claus Braestrup will take over from Dr Christoph Schroeder of TVM Capital who will be leaving the board subsequent to the completed handover.

Dr Claus Braestrup is a member of the Board of the University of Copenhagen, of Bavarian Nordic A/S, of Evolva Holding SA and of Santaris Pharma. He has a background in academic CNS research and has subsequently served as head of Discovery and head of Research and Development in international pharmaceutical companies, including Novo Nordisk A/S, Schering AG and H. Lundbeck A/S. From 2003 to 2008, he served as President and CEO of Lundbeck. Claus Braestrup holds a Master's degree in Chemical Engineering and a Master of Science in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen.

Axel Polack, General Partner of TVM, will join the board. He is a member of the Board of Directors of Noxxon Pharma AG, Genetix Pharmaceuticals Inc. and Invendo Medical GmbH and represents the interests of TVM Capital with f-star GmbH. Before joining TVM Capital, Dr Polack was General Manager of Innovative Technologies Neuherberg GmbH (ITN - now Ascenion GmbH) and prior to this deputy head of an Institute at a Helmholtz Center. He holds a doctorate and a postdoctoral lecture qualification (“Habilitation”) in medicine.

https://www.bionity.com/en/news/118953/probiodrug-announces-supervisory-board-changes.html